Tempus Ai,Inc.(US:TEM) Zhi Tong Cai Jing·2026-01-12 12:11Core Insights - Tempus AI reported preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2025, with total revenue of approximately $1.27 billion, representing a year-over-year growth of about 83% [1] - The company's diagnostic business revenue reached approximately $955 million, a year-over-year increase of about 111%, driven by a 26% increase in tumor testing volume and a 29% increase in genetic testing volume [1] - The data and applications segment generated revenue of $316 million, reflecting a year-over-year growth of about 31%, primarily due to a 38% increase in Insights business [1] Revenue Breakdown - For Q4 2025, Tempus AI reported revenue of approximately $367 million, a year-over-year increase of about 83% [1] - Diagnostic business revenue for Q4 was approximately $266 million, showing a year-over-year growth of about 121%, driven by a 29% increase in tumor testing volume and a 23% increase in genetic testing volume [1] - Data and applications revenue for Q4 was approximately $100 million, with a year-over-year growth of about 25%, and Insights business growth of approximately 68% when excluding the impact of AstraZeneca warrants from Q4 2024 [1] Strategic Outlook - CEO Eric Lefkofsky highlighted that 2025 was an exceptional year for Tempus, with both product lines exceeding initial expectations [2] - The genomic (tumor) product testing volume has accelerated for three consecutive quarters, achieving the highest unit growth rate in years [2] - The company anticipates a strong entry into 2026, with accelerating growth in both main business segments and the inherent financial leverage of its platform being released [2]